临沧子宫脱垂的症状临沧阴道分泌出褐色分泌物,临沧阴道口长了好多颗粒,临沧怀孕几天但不想要孩子,临沧哪家正规医院修复处女膜,临沧子宫出血严重不,临沧看阴道紧缩哪个医院比较好,临沧女性激素六项

SAN FRANCISCO, Nov. 3 (Xinhua) -- Hewlett-Packard Co. (HP) on Thursday introduced its Slate 2 Tablet PC, a business-targeted tablet computer running Windows operating system.Looking like the previous version, Slate 2, featuring an 8.9- inch screen, is upgraded with Intel Atom Z670 processor to deliver faster boot times and improved battery life up to six hours, said HP.It also has a Bluetooth keyboard dock and Swype keyboard which allows users to enter words by sliding a finger or stylus from letter to letter, lifting only between words.The device will be available to customers worldwide for 699 U.S. dollars later this month, according to HP.Slate 500, Slate 2's previous generation running Windows, was introduced last October and sold exclusively to businesses for 800 dollars upon launch.HP said in a statement that the Slate 2 tablet provides instant deployment for business and vertical markets such as education, healthcare, government and retail, where jobs frequently take users away from a traditional desk.The company on Thursday also announced HP 3115m, a new notebook PC targeting business, education and government customers. The notebook will be available in the Americas only next Friday with prices staring at 429 dollars.HP's consumer-oriented tablet TouchPad was killed off in August before former chief executive officer Leo Apotheker resigned. A dropped price from 499 to 99.99 dollars has made the unpopular device sold out in stores across the U.S. and Canada in days.Last Thursday, HP announced it will keep its PC business, saying it will build tablets running Microsoft's upcoming Windows 8 system in 2012.

LOS ANGELES, Oct. 3 (Xinhua) -- An organizer of the World Stem Cell Summit says one of the key problems medical researchers face these days is how to apply their findings in the real world."How do you take the phenomenal scientific research going on in labs and translate it into medical treatments,?" said Bernie Siegel, the founder and co-chair of the summit and executive director of the Genetic Policy Institute, which organized the event."It's a big job to do this, and more than just the science," Siegel said, noting that in a growing field now moving beyond basic lab research, the aim is to connect the people who do the work with those who finance it.The three-day summit, which opened Monday in Pasadena, features more than 150 top international speakers and 50 hours of programming with leaders from science, pharmaceutics, business, policy, ethics, law and other fields.The cell therapy industry, a "nascent" field, has emerged to be a potentially multi-billion business with unlimited potential, Siegel said.Stephen Dalton, a University of Georgia professor, reported that one of the biggest developments in stem cell research in the past year was the realization that cells can be transdifferentiated from one state to another without returning to a pluripotent state.Dalton said the principle was previously supported by a few isolated examples but it was not until 2010 that the idea was widely accepted.Mark Sussman, a professor from San Diego State University, called the identification of lung stem cells from human tissue samples capable of regenerating the highly complex and specialized structures of mature lungs a breakthrough in lung biology and regenerative medicine.He said results presented by the Anversa group in the New England Journal of Medicine demonstrate that human lung stem cells can be expanded in vitro and also retain the capacity to integrate into adult tissue upon introduction into mice.The study, Sussman said, has opened up an entirely new field of possibilities for lung regeneration and potential therapeutic applications for many conditions where treatment options are either very limited or nonexistent.

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

UNITED NATIONS, Jan. 19 (Xinhua) -- China's Permanent Representative to the UN Li Baodong said here Thursday that caution should be called for in metering out sanctions in international affairs.Li made the remarks when addressing a Security Council open debate on the question of justice and rule of law."We are in favor of improving the UN sanction regime on the basis of extensive consultations so as to improve its credibility, procedures and establishing effective monitoring mechanisms and to establish strict criteria, define timelines, " Li said."Sanctions should be only carried out on basis of facts and evidence. Double standards must be avoided. Impacts against civilian lives and social economic development must be minimized," the ambassador said.Stressing that the UN chart and the fundamental principles of international law as established in it should be upheld, Li said rule of law in international relations should be strengthened.The Charter as well as principles of international law established in it constitute the call of rule of law in international relations and represents the bedrock for developing rule of law in international relations, he said."In the conduct of international relations and international affairs, adherence to the Charter and other fundamental principles of international law, such as respect for national sovereignty, non-interference in internal affairs, fulfillment in international obligation in real earnest is the essence of promotion of international rule of law," said Li.According to the Charter, UN Security Council resolutions constitute the integral part of international rule of law. Promotion of international rule of law requires strict implementation of the Security Council resolutions by member states, he added.

BEIJING, Oct. 21 (Xinhua) -- China on Friday urged the European Union (EU) to recognize its full-market economy status at an early date and properly settle trade disputes amid the tumbling world economy."China hopes Belgium will exert its influence to push for an early recognizing of China's full-market economy status and remind the EU to be cautious on and restrain from using trade remedy measures," Vice Premier Wang Qishan told visiting Crown Prince Philippe of Belgium.Wang urged the 27-member bloc, also China's largest trade partner, to properly settle trade disputes with China during the talks at Diaoyutai State Guesthouse in downtown Beijing.Chinese Vice Premier Wang Qishan (R) shakes hands with Belgian Crown Prince Philippe in Beijing, capital of China, Oct. 21, 2011."China has contributed a lot to the world economy by recording a 9.4 percent growth in the first three quarters of this year while adjusting its economic structure and managing inflation expectations," Wang said.Prince Philippe, accompanied by a 450-member business delegation, is here to tap the Chinese market and seek investments from China, the world's top holder of foreign exchange reserves.During the 10-day trip, the delegation will visit the Chinese cities of Tianjin, Guangzhou, Shenzhen, Shanghai and Chongqing and is expected to sign about 40 contracts.Wang said China will expand two-way investment with Belgium, and enhance support to the two states' small and medium-sized enterprises via the China-Belgium direct equity investment fund.China-Belgium trade has continued to surge since the two states forged diplomatic ties in 1971, when the bilateral trade volume was only 20 million U.S. dollars, much less than the 22.1 billion U.S. dollar record in 2010."We could expand cooperation in two-way investment, trade, finance, chemical industry, environmental protection, logistics, and green economy," Wang said.